Context Therapeutics Inc.
CNTX · XNASCIK 1842952fmd_0ZYKVF30F0S5BKCZWYPSKJHGV7Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2020 to Sep 30, 2026, 27 periods
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Net interest income | – | (0) | 1 | 1 | – | – |
| Research and development | 2 | 4 | 7 | 18 | 23 | 32 |
| Operating income | (3) | (11) | (15) | (25) | (30) | (40) |
| Interest expense | 1 | 0 | – | – | – | – |
| Interest and investment income | – | – | – | 1 | 3 | 3 |
| Other non-operating income (expense) | 0 | 0 | (0) | (0) | (0) | 0 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 7 | (10) | (15) | (24) | (27) | (36) |
| Net income to common shareholders | 1 | (10) | – | – | – | – |